Jean Kaseya, head of Africa Centers for Disease Control and Prevention, stood before reporters with a promise that cuts against the most pressing health crisis on the continent right now: by the end of 2026, Africa will have a vaccine against the Bundibugyo strain of Ebola. The commitment comes as the Democratic Republic of Congo grapples with an outbreak that has claimed at least 246 lives among 1,077 suspected cases since the crisis was declared on May 15.
The Bundibugyo outbreak is particularly menacing because, until now, there has been no approved vaccine or treatment specifically designed to combat this strain. For months, health workers have operated without the critical tools that could turn the tide against transmission. That gap in medical armament is what makes Kaseya's pledge so significant—it signals both urgency and confidence from Africa's highest health authority.
"What we can tell you for sure, by the end of this year, 2026, Africa CDC will make sure that we have a vaccine and medicine against Bundibugyo," Kaseya told reporters in an online briefing. The statement reflects a shift in how the continent approaches health crises, with African institutions taking the lead in developing solutions tailored to African diseases. He emphasized that "some candidates" for a vaccine are already in development, and that African leaders have signaled their willingness to invest at both technical and strategic levels.
The path forward is not straightforward. Kaseya revealed that he had recently received word from Russia's Ministry of Health claiming to have developed a vaccine against the strain. However, clarification from his team indicated that the Russian vaccine actually targets the Zaire strain of Ebola, not Bundibugyo. Upcoming discussions with Moscow's Gamaleya National Research Center may shed light on whether insights from the Zaire vaccine could inform efforts against Bundibugyo, though such cross-strain effectiveness remains uncertain.
What's clear is that the timeline is tight and the stakes are high. Every month that passes without an approved vaccine represents a window of vulnerability for health workers and affected communities across the DRC. The outbreak has already tested local systems and exposed the global inequity in vaccine development—wealthy nations have benefited from rapid vaccine development during recent health emergencies, while African nations have historically waited for solutions developed elsewhere.
This push to develop a Bundibugyo vaccine by year's end represents a different model: African scientists and institutions working with determination and continental backing to solve an African health emergency on African terms. It's an approach that recognizes both the urgency of the moment and the capacity that exists within the continent when resources and political will align.
The figures underscore the human dimension of this work. Behind each of the 246 deaths are families and communities transformed by loss. Behind each suspected case is a person whose life hangs in the balance while vaccines remain out of reach. Kaseya's promise carries the weight of that reality—and the hope that by year's end, a new tool will be in health workers' hands.